UK cost agency rejects Amgen’s virus-based cancer drug

An Amgen sign is seen at the company's office in South San FranciscoA first-in-class melanoma drug from Amgen based on a tumor-killing virus has been deemed not worth using on Britain's state health service by the country's cost-effectiveness agency NICE. The National Institute for Health and Care Excellence said on Wednesday there was not enough evidence to be able to say whether Imlygic, also known as talimogene laherparepvec or "T-Vec", was as clinically effective as other drugs for the deadly skin cancer. Imlygic uses a herpes simplex virus, the type that causes cold sores, which has been modified to only infect cancer cells.

Sexual Health News Headlines – Yahoo! News